Every material Form 8-K Pyxis Oncology, Inc. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pyxis Oncology reported a third-quarter 2026 net loss of $20.0 million, or $0.24 per share, down from $22.0 million, or $0.35 per share, a year earlier. The company reported no revenue in either quarter, and it held $57.0 million in cash and short-term investments at September 30, 2026. It says an October 1, 2026 public offering with about $110.0 million in upfront gross proceeds should fund operations into the first half of 2028.
Net loss was $20.0 million, or $(0.24) per share, for the quarter ended September 30, 2026, versus $22.0 million, or $(0.35) per share, a year earlier.
Research and development expenses were $16.6 million, down from $17.8 million; general and administrative expenses were $4.0 million, down from $5.7 million.
Cash and short-term investments were $57.0 million at September 30, 2026; the October 2026 offering included milestone-linked warrants that could add about $172.6 million if exercised in full.
FDA feedback on dose selection is expected in the first quarter of 2027, and the global Phase 3 Headliner SM trial is planned to start in mid-2027.
Pyxis Oncology closed an underwritten public offering on October 1, 2026, selling 36,047,919 shares and pre-funded warrants for 1,883,121 shares, each paired with common warrants, for a combined price of $2.90 per share. The company expects net proceeds of about $102.8 million, and says its cash plus these proceeds will fund operations into the first half of 2028. The common warrants cannot be exercised until stockholders approve an increase in authorized shares, and if they are exercised, the company would receive about $162.2 million more, net of a 6% solicitation fee.
Offering: 36,047,919 shares and 1,883,121 pre-funded warrants, with common warrants for up to 49,310,352 shares; closed October 1, 2026
Combined public offering price of $2.90 per share; common warrants have a $3.50 exercise price
Net proceeds of about $102.8 million; up to about $162.2 million more if all warrants are exercised, net of a 6% fee
Warrants require a stockholder vote to increase authorized shares, with a meeting planned within 60 days of closing; the company says funds may be insufficient for the Phase 3 Headliner trial if warrants go unexercised
Pyxis Oncology (Nasdaq: PYXS) reported updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma, with a data cutoff of August 18, 2026. The company reported a 36% confirmed objective response rate among 33 efficacy-evaluable patients and said no new safety signals were observed, but 54.3% of the 35 safety-evaluable patients had treatment-related adverse events of grade 3 or higher. The company plans to initiate a pivotal Phase 3 study in mid-2027.
Confirmed objective response rate of 36% (12 of 33) and disease control rate of 94% (31 of 33)
Median progression-free survival of 6.2 months; 12-month overall survival probability of 79%; median overall survival not yet reached
Grade 3 or higher treatment-related adverse events in 54.3% of patients (19 of 35); 5 patients (14.3%) discontinued treatment due to these events
End of Phase 2 meeting with the FDA expected in the first quarter of 2027; Phase 3 Headliner trial planned to start in mid-2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pyxis Oncology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →